Skip to content
Inciteful Med

Validation & Orientation: What is Behçet Disease?

Last updated:

Behçet's disease is a rare, chronic condition that causes inflammation in the blood vessels. While there is no cure, advanced treatments like biologics are highly effective at managing flares, allowing many patients to achieve long-term remission and maintain their quality of life.

Key Takeaways

  • • Behçet's disease is a type of systemic vasculitis that causes chronic blood vessel inflammation.
  • • The condition is highly treatable with modern medications like biologics, with the main goal being long-term remission.
  • • The HLA-B51 gene is a known genetic risk factor, but having it does not guarantee you will develop the disease.
  • • Family planning is entirely possible but requires careful medication management with your healthcare team.

Receiving a diagnosis of Behçet’s disease can feel isolating, especially because it is rare in many parts of the world. However, understanding the mechanics of the condition is the first step toward regaining a sense of control. Behçet’s is a chronic multisystem inflammatory disorder, which means it can cause inflammation in various parts of the body over a long period [1][2]. It is formally classified as a type of systemic vasculitis, a condition where the immune system mistakenly attacks the blood vessels [3][4].

Three Stabilizing Facts

If you are currently in a panic spiral, please hold onto these three evidence-based truths:

  1. It is highly treatable: While there is currently no cure, modern medicine has made incredible strides. Advanced therapies, including biologics (targeted medications that calm specific parts of the immune system), are highly effective at controlling inflammation and preventing long-term damage [5][6].
  2. Remission is the goal: The disease is typically “episodic,” meaning it moves in cycles of flares (active symptoms) and remissions (quiet periods). Many patients achieve long periods of stability where the disease does not interfere with daily life [7][8].
  3. You are not alone: Although rare in the West, this condition has been studied for decades. Specialized care teams are equipped to manage the multisystem nature of the disorder and protect your long-term health [9][10].

The “Silk Road” Connection

Behçet’s disease is often nicknamed the “Silk Road Disease.” This is because it is most frequently diagnosed in people with ancestry from regions along the ancient Silk Road trading route, stretching from eastern Asia (like Japan and Korea) through the Middle East (Turkey and Iran) to the Mediterranean [11][12].

  • Global Prevalence: In Turkey, the prevalence can be as high as 420 per 100,000 people [11].
  • Western Rarity: In countries like the United States or the Netherlands, it is much rarer, affecting roughly 1 to 2 in 100,000 people [11][13].
  • Typical Onset: Most people first notice symptoms in their 20s or 30s, though it can occasionally appear in children or older adults [14][15].

What is Happening Inside the Body?

In Behçet’s, the immune system is “hyper-reactive.” This is driven by two main factors:

1. The Genetic Blueprint (HLA-B51)
The most significant genetic risk factor is a marker called HLA-B51 [16]. Think of this as a piece of code in your DNA that makes your immune system more likely to overreact to environmental triggers [17].

  • Important Note: Having the HLA-B51 gene does not guarantee you will develop Behçet’s, and lacking it does not rule the disease out [16][18]. It is just one piece of the puzzle.

2. Overactive Neutrophils
Neutrophils are a type of white blood cell that normally acts as your body’s first responders to infection [19]. In Behçet’s, these cells become hyper-reactive [20]. They may spontaneously undergo a process called NETosis, where they release “nets” of DNA and proteins intended to trap germs [21][22]. Instead, these nets cause inflammation and damage to the lining of the blood vessels, which can lead to blood clots or ulcers [20][23].

Family Planning and Moving Forward

Because Behçet’s often appears during prime reproductive years, family planning is an important conversation. The disease itself does not typically prevent pregnancy, but some of the powerful medications used to treat severe flares can be harmful to a developing fetus [24]. Your care team will help you choose safe, effective options if you are planning to build a family [24].

Because Behçet’s can affect everything from the mouth and skin to the eyes and joints, your care will involve a coordinated team [2]. The primary goal is to suppress your overactive neutrophils and protect your blood vessels from inflammation [10][21]. With early diagnosis and a consistent management plan, you can return to the Home Page to explore how to navigate your daily life.

Frequently Asked Questions

What is Behçet's disease?
Behçet's disease is a chronic condition classified as a systemic vasculitis, meaning it causes inflammation in the blood vessels. It operates in cycles of flares and remissions.
Is Behçet's disease curable?
While there is currently no cure, Behçet's disease is highly treatable. Modern medications, including biologics, can effectively control inflammation and help patients achieve long periods of remission where the disease does not interfere with daily life.
What role does the HLA-B51 gene play in Behçet's disease?
The HLA-B51 gene is a genetic marker that makes your immune system more likely to overreact to triggers. However, having this gene does not guarantee you will develop the condition, and lacking it does not rule it out.
Can I still have a family if I have Behçet's disease?
Yes, the disease itself does not usually prevent pregnancy. However, because some medications used for severe flares can harm a developing fetus, it is crucial to discuss family planning with your care team to find safe treatment options.
How do I know if I am having a Behçet's disease flare?
A flare involves active symptoms of inflammation caused by hyper-reactive immune cells, which may cause ulcers or other issues. Your doctor can help you learn to distinguish between a true disease flare and an unrelated minor infection.

Questions for Your Doctor

  • • Based on my symptoms, do I meet the International Criteria for Behçet's Disease (ICBD)?
  • • How can we distinguish between a 'flare' of Behçet’s and a minor infection or unrelated symptom?
  • • Can you explain how my genetic markers and neutrophil activity influence the treatment options you are considering?
  • • Since this condition can affect fertility and pregnancy, how do my current medications impact my family planning goals?

Questions for You

  • • How am I feeling emotionally after this diagnosis, and would I benefit from a support group or mental health professional?
  • • Do I have a reliable system, such as a journal or app, for tracking my symptoms and medications to share with my medical team?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Behçet's disease and risk of vascular events.

    Balta S, Balta I, Ozturk C, et al.

    Current opinion in cardiology 2016; (31(4)):451-7 doi:10.1097/HCO.0000000000000281.

    PMID: 27152661
  2. 2

    Widespread venous thrombosis: Unveiling a complex case of Behçet's disease with a literature perspective.

    Liu B, Tan C

    Open medicine (Warsaw, Poland) 2025; (20(1)):20251199 doi:10.1515/med-2025-1199.

    PMID: 40823180
  3. 3

    [An aortic and femoral aneurysm revealing Behçet's disease].

    Lyazidi Y, Abissegue Y, Chtata HT, Taberkant M

    Journal des maladies vasculaires 2015; (40(6)):399-401.

    PMID: 26460187
  4. 4

    Multiple Intracranial Aneurysms Associated with Behçet's Disease.

    Ha S, Kim J, Kim CG, Jang SJ

    Journal of cerebrovascular and endovascular neurosurgery 2016; (18(1)):32-7 doi:10.7461/jcen.2016.18.1.32.

    PMID: 27114964
  5. 5

    Adamantiades-Behçet's disease therapy: current treatment options and recommendations with regard to the COVID-19 pandemic.

    Trevisini S, Trevisan G, Zalaudek I, Bonin S

    Dermatologic therapy 2022; (35(3)):e15286 doi:10.1111/dth.15286.

    PMID: 34962035
  6. 6

    Update on the treatment of Behçet's syndrome.

    Esatoglu SN, Hatemi G

    Internal and emergency medicine 2019; (14(5)):661-675 doi:10.1007/s11739-019-02035-1.

    PMID: 30684097
  7. 7

    Management of patients with Behçet's disease during the COVID-19 pandemic.

    Dursun R, Temiz SA, Özer İ, et al.

    Dermatologic therapy 2020; (33(6)):e14063 doi:10.1111/dth.14063.

    PMID: 32710599
  8. 8

    Low Level Laser Therapy to Reduce Recurrent Oral Ulcers in Behçet's Disease.

    Babu DB, Chavva S, Waghray S, et al.

    Case reports in dentistry 2016; (2016()):4283986 doi:10.1155/2016/4283986.

    PMID: 27555969
  9. 9

    Carotid artery aneurysm as the initial presentation of Behçet's disease: A case report.

    Bengrad A, Laarouchi A, Ouhmich M, et al.

    Journal of vascular surgery cases and innovative techniques 2026; (12(1)):102011 doi:10.1016/j.jvscit.2025.102011.

    PMID: 41323528
  10. 10

    Isolated brachial artery aneurysm: a rare presentation of paediatric Behçet's disease.

    Naik AL, Savlania A, Gupta A, et al.

    Annals of the Royal College of Surgeons of England 2021; (103(3)):e94-e97 doi:10.1308/rcsann.2020.7037.

    PMID: 33645285
  11. 11

    Behçet's disease, hospital-based prevalence and manifestations in the Rotterdam area.

    Kappen JH, van Dijk EH, Baak-Dijkstra M, et al.

    The Netherlands journal of medicine 2015; (73(10)):471-7.

    PMID: 26687263
  12. 12

    Multiorgan involvement of Behçet's disease in a young woman.

    Tamer F, Gülru Erdoğan F, Dinçer Rota D, Yıldırım D

    Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2018; (27(3)):153-154.

    PMID: 30244267
  13. 13

    Incidence and prevalence of Behçet's disease in Oslo, Norway: a two-decade population-based analysis.

    Lorentsen JLL, Brunborg C, Aasebø AT, et al.

    Rheumatology (Oxford, England) 2025; (64(8)):4703-4712 doi:10.1093/rheumatology/keaf224.

    PMID: 40279276
  14. 14

    Relationship between age at onset and clinical characteristics of Behçet's disease.

    Ghembaza MEA, Lounici A

    Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2018; (27(4)):175-177.

    PMID: 30564829
  15. 15

    Behçet's disease unraveled: Insights into clinical manifestations, diagnosis, and management.

    Alghamdi M, Lindsey S

    Medicine 2025; (104(49)):e44614 doi:10.1097/MD.0000000000044614.

    PMID: 41367023
  16. 16

    The association of Behçet's syndrome with HLA-B51 as understood in 2021.

    Takeno M

    Current opinion in rheumatology 2022; (34(1)):4-9 doi:10.1097/BOR.0000000000000846.

    PMID: 34690278
  17. 17

    Case of elderly onset possible neuro-Behçet's disease with HLA-B51 homozygosity.

    Shiraishi W, Tsujimoto Y, Matsuyoshi A, Hashimoto T

    BMJ case reports 2023; (16(6)) doi:10.1136/bcr-2022-252033.

    PMID: 37263675
  18. 18

    Clinical trait-specific genetic analysis in Behçet's disease identifies novel loci associated with ocular and neurological involvement.

    Casares-Marfil D, Esencan D, Alibaz-Oner F, et al.

    Clinical immunology (Orlando, Fla.) 2023; (253()):109657 doi:10.1016/j.clim.2023.109657.

    PMID: 37271218
  19. 19

    Reduction of Neutrophil Activation by Phosphodiesterase 4 Blockade in Behçet's Disease.

    Le Joncour A, Régnier P, Maciejewski-Duval A, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2023; (75(9)):1628-1637 doi:10.1002/art.42486.

    PMID: 36862398
  20. 20

    Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Behçet's disease.

    Safi R, Kallas R, Bardawil T, et al.

    Journal of dermatological science 2018; (92(2)):143-150 doi:10.1016/j.jdermsci.2018.08.010.

    PMID: 30237006
  21. 21

    Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease.

    Le Joncour A, Martos R, Loyau S, et al.

    Annals of the rheumatic diseases 2019; (78(9)):1274-1282 doi:10.1136/annrheumdis-2018-214335.

    PMID: 31147357
  22. 22

    Presence of neutrophil extracellular traps in superficial venous thrombosis of Behçet's disease.

    Kawakami T, Yokoyama K, Ikeda T, et al.

    The Journal of dermatology 2022; (49(7)):741-745 doi:10.1111/1346-8138.16391.

    PMID: 35434809
  23. 23

    Mucocutaneous manifestations of Behçet's disease: Pathogenesis and management from perspectives of vasculitis.

    Kim D, Nakamura K, Kaneko F, et al.

    Frontiers in medicine 2022; (9()):987393 doi:10.3389/fmed.2022.987393.

    PMID: 36530905
  24. 24

    The Greek (Hellenic) rheumatology over the years: from ancient to modern times.

    Sakkas LI, Tronzas P

    Rheumatology international 2019; (39(6)):947-955 doi:10.1007/s00296-019-04261-4.

    PMID: 30805680

This page provides a general overview of Behçet's disease for educational purposes only. Always consult your rheumatologist or healthcare provider for an official diagnosis and personalized treatment plan.

Stay up to date

Get notified when new research about Behçet disease is published.

No spam. Unsubscribe anytime.